Tatva Chintan Pharma Chem Ltd

- No explicit mention of any current or future fundraising through debt or equity in the transcript. - Loans and short-term borrowings have increased recently, but no indication of new fundraising plans. - Management focuses on capital expenditure funded internally, with planned capex of INR 100 crores (FY27) and INR 175 crores (FY28) for the Jolva plant. - Dividend payout policy discussed—around 10% of net profit distributed; 90% earnings retained for reinvestment. - No remarks or questions related to raising new debt or equity capital during the call.

- Current financial year (FY27) capex: INR 100 crores, mainly for Jolva plant. - Next financial year (FY28) capex: INR 175 crores, also largely for Jolva plant. - Total estimated investment for Jolva project: approx. INR 250-270 crores. - Jolva plant construction expected to start by mid-2026, with commercial production targeted in early 2028 (January to March). - Additional minor capex (~INR 10-12 crores per year) planned to remove bottlenecks and ramp up revenue at existing Dahej facility. - Jolva project designed to enhance scalability, operational efficiency, and accommodate new agro intermediates plus growth in existing products. - Focus on building infrastructure for future growth, including semiconductor chemicals and electrolyte salts segments.

- FY27 revenue growth guidance is around 25%, with EBITDA margins targeted between 20%-22%. - Structured Directing Agents (SDA) expected to grow at least 20% in FY27, reaching INR250-300 crores. - Electrolyte Salts segment to become a relevant contributor, targeting 8%-10% of overall revenue, with ramp-ups continuing through FY27 and beyond. - Pharma segment to add INR70-75 crores in FY27 through new product commercialization. - Agro intermediates demand is stable with improved commercial traction; new product launches expected post-Jolva plant commissioning (~early 2028). - Semiconductor chemicals segment beginning commercial dispatch with gradual scale-up expected through 2027-28. - Jolva greenfield project planned to start commercial production around Jan 2028, potentially doubling capacity and revenues in PASC segment. - Management remains cautious on geopolitical uncertainties but optimistic about a structured growth phase over the next 2 years.

- Tatva Chintan expects revenue growth of around 25% for FY27, driven by segments like Electrolyte Salts (ESS), Pharma, Agro, Specialty Chemicals (PASC), and Structured Directing Agents (SDA). - EBITDA margin guidance is maintained at 20% to 22%, supported by better product mix and operating leverage. - The new Dahej facility ramp-up aims to scale revenue up to INR 850-900 crores by FY28 with minor capex to remove bottlenecks. - The Jolva greenfield project is expected to start commercial production by early 2028, with estimated investment of INR 250-270 crores and potential revenue around INR 400-500 crores in Phase 1. - Electrolyte salts segment, currently 8-10% of business, is a key growth driver with significant ramp-up expected from FY27 onwards. - Despite raw material price pressures, efficient cost absorption and customer cooperation should sustain margins and profits. - Semiconductor chemicals segment is in early commercialization with confident long-term growth prospects.

- The company receives annual forecasts from customers and orders are released based on these forecasts. - Forecasts are generally precise except during unpredictable demand fluctuations. - Demand became volatile over the last 2 years due to inventory pile-ups post-COVID but is now normalizing with regular orders. - For the Pharma, Agro, and Specialty Chemicals (PASC) segment, there is good visibility of orders till the end of the current calendar year and likely continuation into the next year. - Semiconductor chemicals segment is at the early commercialization stage with first plant scale batch dispatch expected this quarter; gradual scale-up expected through 2028-29. - Electrolyte Salts segment is gradually scaling with increasing order traction, including new hybrid battery applications starting commercial ramp-up by late 2027. - Overall, the company expects steady order flow and strong demand visibility across key segments over the next 2 years.